Tempus AI, Inc. (NASDAQ:TEM) Receives $68.64 Consensus Price Target from Brokerages

Tempus AI, Inc. (NASDAQ:TEM) has been assigned an average rating of “Hold” from the fifteen research firms that are currently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, four have given a hold recommendation and nine have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $68.6429.

A number of equities analysts recently weighed in on the company. Robert W. Baird assumed coverage on Tempus AI in a report on Tuesday, February 17th. They set an “outperform” rating and a $59.00 price objective on the stock. Mizuho assumed coverage on Tempus AI in a report on Thursday, February 19th. They set an “outperform” rating and a $100.00 price objective on the stock. Guggenheim decreased their price objective on Tempus AI from $95.00 to $60.00 and set a “buy” rating on the stock in a report on Monday, March 30th. Wolfe Research assumed coverage on Tempus AI in a report on Tuesday, June 2nd. They set a “peer perform” rating on the stock. Finally, Jefferies Financial Group assumed coverage on Tempus AI in a report on Monday, April 13th. They set an “underperform” rating and a $35.00 price objective on the stock.

Tempus AI Stock Up 9.4%

TEM stock opened at $52.32 on Tuesday. The company has a current ratio of 3.31, a quick ratio of 3.15 and a debt-to-equity ratio of 2.96. The company’s 50 day moving average is $49.42 and its 200 day moving average is $56.51. The stock has a market cap of $9.40 billion, a price-to-earnings ratio of -30.42 and a beta of 3.64. Tempus AI has a 1-year low of $41.73 and a 1-year high of $104.32.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.08. The company had revenue of $348.12 million for the quarter, compared to analysts’ expectations of $345.44 million. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. Tempus AI’s revenue for the quarter was up 36.1% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.24) earnings per share. Sell-side analysts predict that Tempus AI will post -1.35 EPS for the current fiscal year.

Insider Activity at Tempus AI

In related news, CEO Ryan Fukushima sold 13,550 shares of the firm’s stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $44.07, for a total transaction of $597,148.50. Following the transaction, the chief executive officer directly owned 603,558 shares of the company’s stock, valued at approximately $26,598,801.06. This trade represents a 2.20% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Andrew Polovin sold 8,703 shares of the firm’s stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $44.07, for a total value of $383,541.21. Following the transaction, the executive vice president directly owned 128,215 shares in the company, valued at approximately $5,650,435.05. This represents a 6.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 558,557 shares of company stock worth $26,611,939 in the last quarter. 24.26% of the stock is owned by company insiders.

Hedge Funds Weigh In On Tempus AI

A number of large investors have recently bought and sold shares of TEM. GC Wealth Management RIA LLC purchased a new position in Tempus AI in the 4th quarter worth approximately $399,267,000. Vanguard Group Inc. increased its stake in Tempus AI by 22.1% in the 3rd quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company’s stock worth $762,032,000 after purchasing an additional 1,706,837 shares during the period. Voloridge Investment Management LLC increased its stake in Tempus AI by 183.0% in the 3rd quarter. Voloridge Investment Management LLC now owns 1,607,083 shares of the company’s stock worth $129,708,000 after purchasing an additional 1,039,176 shares during the period. BNP Paribas Financial Markets increased its stake in Tempus AI by 312.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,274,549 shares of the company’s stock worth $102,869,000 after purchasing an additional 965,730 shares during the period. Finally, AQR Capital Management LLC purchased a new position in Tempus AI in the 2nd quarter worth approximately $54,020,000. 24.22% of the stock is owned by hedge funds and other institutional investors.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.